Skip to Main Content

WASHINGTON — A new analysis from the drug industry’s top lobbying group asserts that many Americans are feeling more of a pinch paying for their prescription drugs because customers are not fully benefitting from health insurers’ negotiations with drug makers.

The new report, shared exclusively with STAT by the Pharmaceutical Research and Manufacturers of America, is the latest in an ongoing volley between drug makers, health insurers, and pharmacy-benefits managers. They are the major players, along with public officials, in the debate over drug affordability.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!